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ABSTRACT
Aberrant methylation of DNA has been shown to play
an important role in a variety of human cancers,
developmental disorders and aging. Hence, aberrant
methylationpatternsingenescanbeamolecularmar-
ker for such conditions. Therefore, a reliable but
uncomplicated method to detect DNA methylation
is preferred, not merely for research purposes but
for daily clinical practice. To achieve these aims, we
have established a precise system to identify DNA
methylation patterns based on an oligonucleotide
microarray technology. Our microarray method has
an advantage over conventional methods and is
unique because it allows the precise measurement
of the methylation patterns within a target region.
Our simple signal detection system depends on
using an avidin–biotinylated peroxidase complex
and does not require an expensive laser scanner or
hazardous radioisotope. In this study, we applied our
technique to detect promoter methylation status of
O
6-methylguanine-DNA methyltransferase (MGMT)
gene. Our easy-handling technology provided repro-
ducible and precise measurement of methylated
CpGs in MGMT promoter and, thus, our method
may bring about a potential evolution in the handling
of a variety of high-throughput DNA methylation ana-
lyses for clinical purposes.
INTRODUCTION
It is now clear that aberrant methylation of CpG island-
stretches within a promoter, causing silencing of tumor
suppressor genes, is a widespread phenomenon in cancer
cells (1). Abnormal methylation also occurs at CpG-rich regu-
latory elements in intronic and coding parts of genes in certain
tumors (2). At the same time, genome-wide hypomethylation
ofDNAisgenerallyobservedintumorcells. Therefore,cancer
can be understood not only as a genetic but also as an epi-
genetic disease.
Methylation density in promoter CpG islands was indicated
to be important for gene silencing rather than methylation that
occurred at a limited number of CpG islands in the promoter
(3). Since tumors can progressively but differently accumulate
methylation at the promoter CpG islands of multiple cancer-
related genes, understanding and measurement of promoter
methylation patterns on each gene is also required. The tech-
nique commonly used for the methylation analysis is based on
the bisulﬁte modiﬁcation of the genomic DNA. Since sodium
bisulﬁte treatment exclusively converts unmethylated cytosine
to uracil under appropriate conditions (4), subsequent analy-
sis to differentiate unconverted cytosine from converted
uracil enables us to know the primary methylation status.
Methylation-speciﬁc PCR (MSP) (5) is widely used to analyze
promoter methylation, but only a limited number of CpG
islands can be analyzed by this method. Accordingly, it does
not fulﬁll the need to quantify the level of methylation relating
to the gene silencing. Conversely, bisulﬁte DNA sequencing
(6–8) provides precise methylation status over an ampliﬁed
region, but it requires large-scale sequencing of multiple plas-
mid clones. Several groups have recently shown that the
methylation status can be precisely achieved by microarray-
based technologies (9–12). These assays can be applied to
analyze number of CpG island methylation of multiple
genes atthe sametime.There,however,remains arequirement
to develop an inexpensive and high-throughput but still quant-
itative method to screen the methylation status of multiple
genes, especially for the purpose of medical diagnosis.
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doi:10.1093/nar/gni046We have recently modiﬁed the original microarray strategy
and developed an alternative microarray technique that allows
immobilization of non-modiﬁed oligonucleotides on solid
support by using the polycarbodiimide-coated slide (13).
This results in a substantial cost saving in the fabrication of
an array. Therefore, we applied this method for the CpG island
methylationmicroarray,which canefﬁcientlyscan themethyl-
ated cytosines in tumor genome.
In this study, we describe a novel microarray procedure
and its application for the mapping of methylated CpG
islands in human O
6-methylguanine-DNA methyltransferase
(MGMT) gene in the properties of colorectal cancers
(CRCs) (3). The technology uses an avidin–biotinylated per-
oxidase complex (ABC) method to visualize hybridization
signals (14,15) and the high-quality methylation microarray
signals can be detected with good reproducibility. This
detection system does not rely on an expensive ﬂuorescence
detection system or hazardous radioisotope. The detection of
methylation proﬁles by the ABC method, without com-
promising the quality of the DNA chip, results in a further
substantial cost saving. Furthermore, our hybridization and
detection procedures can be achieved within 2 h, whereas
widely used microarray technologies are time-consuming
and takes up to 10 h. The approach described here provides
an effective tool, which produces speciﬁc and reproducible
hybridization signals in DNA-chip methylation proﬁling.
MATERIALS AND METHODS
Synthesis of oligonucleotide
Oligonucleotides labeled with 50-biotin were synthesized on
an ABI 3900 DNA synthesizer at a 0.2 mmol scale using the
standard phosphoamidite method. The labeled oligonuc-
leotides were puriﬁed by reverse-phase high-performance
liquid chromatography using a standard procedure and dried
in vacuo. Non-modiﬁed oligonucleotides were also synthes-
ized on an ABI 3900 DNA synthesizer at a 0.2 mmol scale
using the standard procedures. The non-modiﬁed oligonuc-
leotides were then puriﬁed on a reverse-phase cartridge fol-
lowing a standard procedure and dried in vacuo.
Human tissue samples and DNA preparation
Tumor tissues from CRC patients and corresponding normal
mucosal samples used in this study were surgically removed
at Okayama University Hospital as described previously (3).
Tissue samples were treated with proteinase K with the
concentration of 1–2 mg/ml at 50–55 C overnight or 24 h
before phenol–chloroform procedure. Genomic DNA was
extracted using the standard phenol–chloroform procedure,
precipitated by ethanol and dissolved in TE buffer.
Bisulfite modification
Bisulﬁte modiﬁcation of DNA samples (up to 1 mg) was per-
formed using the CpGenome DNA modiﬁcation kit (Intergen,
Purchase, NY). The modiﬁed DNA was used immediately or
stored at  20 C for further analysis.
Bisulfite nucleotide sequencing procedure
Nested PCR was performed to amplify a region within the
exon 1 of the MGMT promoter from nt 685 to 1195 (16). The
nucleotide numbering refers to accession nos. HSMETDMET
and HSU95038. In the presence of 10–40 ng of bisulﬁted
DNA as a template, ﬁrst-round PCR was carried out using
sense primer 1 [50-GGTATAGAGTTTTAGGCGGAAGTT-
30 (nt 675–698)] and antisense primer 2 [50-CAACACCTA-
CAAAACCACTCGAAA-30 (nt 1177–1200)]. To obtain pro-
ducts for sequencing, a second set of PCR was run with the use
of methylation-speciﬁc sense primer 3 [50-TTTAGGCGGAA-
GTTGGGAGGCGTC-30 (from nt 685 to 708)] and antisense
primer4[50-CCTACAAAACCACTCGAAACTACC-30(from
1172 nt to 1195)]. With these primers, the methylated allele in
the ﬁrst PCR product can be ampliﬁed. With the use of
unmethylated-speciﬁc sense primer 5 [50-TTTAGGCGGAA-
GTTGGGAGGTGTT-30 (from nt 685 to 708)] and antisense
primer 4, unmethylated alleles can be ampliﬁed. The positions
of bisulﬁte-induced deamination of cytosine residues in the
primer sequences are shown in bold.
Ampliﬁcation consisted of 37 cycles, with denaturation at
94 C for 30 s, annealing at 58 C for 30 s and extension at 72 C
for 40 s. The initial denaturation was at 94 C for 5 min.
Finally, the PCR mixture was incubated at 72 C for
10 min. An aliquot of 15 ng of the ﬁrst round of PCR products
was used for a second-round ampliﬁcation under the condi-
tions described above. The PCR products were puriﬁed using
the Qiaquick PCR puriﬁcation kit (Qiagen, Valencia, CA).
Subsequently, second-round products were cloned into the
pGEM-Teasy vector (Promega, Madison, WI) following
the manufacturer’s protocol. The plasmids were ampliﬁed
in Escherichia coli JM109 (Toyobo, Osaka, Japan) and were
puriﬁed by a Plasmid puriﬁcation kit (Qiagen). PCR products
from these plasmids, originated from fully-, partially- and
non-methylated DNA, were veriﬁed by sequencing as the
bisulﬁte-modiﬁed nucleotide alteration status. In order to
label those originally as fully-, partially- and non-
methylated targets, PCRs were performed using biotinylated
forward and reverse primers with the same condition as used
above, followed by the veriﬁcation of the sequence with ABI
310 genetic analyzer.
PCR amplification of clinical samples for
microarray analysis
PCRs were performed using biotinylated forward and reverse
primers with a sample DNA as template. The PCR condition
was same as that used above, except for the use of biotinylated
forward (50-TTTAGGIGGAAGTTGGGAGGIGTI-30) and
reverse (50-CCTACAAAACCACTCIAAACTACC-30) pri-
mers. Subsequently, biotinylated PCR products were puriﬁed
using the Qiaquick PCR puriﬁcation kit. The products were
also examined on the 1% agarose gel.
Microarray procedure
Non-modiﬁed oligonucleotides were spotted in duplicate on
CarboStation
TMplastic slide (NisshinboIndustriesInc.,Chiba,
Japan) with spots of  250 mm in diameter and a spot-to-spot
distance of 600 mm using a customized microarray robot (13).
To analyze each CpG position, two oligonucleotides (spotted
at 50 mM solution), reﬂecting methylated and unmethylated
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according to the manufacturer’s procedure. The oligonuc-
leotides were designed to match the bisulﬁte-modiﬁed DNA
fragments.
Each biotinylated PCR product was dissolved in distilled
water and denatured for 1 min at 95 C. Uni-Hyb hybridization
solution (Telechem International Inc., Sunnyvale, CA) was
added (80% v/v Uni-Hyb hybridization solution; total volume
12 ml) and the hybridization solution was applied by capillary
action between a slide and cover slip. The slide was incubated
for 1 h at 55 C in a closed hybridization cassette. Arrays were
washed at room temperature in 2· SSC for 5 min. Sub-
sequently, a color development reaction on the slide was per-
formed according to the ABC method utilizing a 4,4,40,40-
tetramethyl benzidine solution for visualization (14,15).
After 15 min, color development reaction was terminated
by washing the arrays with distilled water.
Signal detection and data analysis
The arrays were imaged on a GT8700-F scanner (Epson,
Nagano, Japan). Signals on arrays were converted to TIFF
images,and the signal intensities were quantiﬁedby an ImageJ
software from the National Institutes of Health. The ImageJ
software is freely available on the website (http://rsb.info.nih.
gov/nih-image/Default.html). The analysis was performed by
selecting a circular region of pixels and determining the values
along the perimeter. The mean hybridization intensity of these
pixels was then calculated. Unless stated otherwise, the aver-
age signal values were taken from two spots on two slides
proceeded in parallel.
RESULTS
Detection principle
Figure 1 outlines our strategy for the DNA methylation ana-
lysis.Inorder todistinguishbetweenmethylatedandunmethy-
lated state of the CpG sites in target sequence, DNA from all
samples was ﬁrst treated with bisulﬁte, converting unmethyl-
ated cytosine to uracil, while conserving methylated cytosine.
The region of interest was then ampliﬁed by PCR with biot-
inylated primers, converting originally unmethylated CpG
dinucleotide to TpG, while conserving originally methylated
CpG. Biotinylated target DNA was then hybridized to the
arrayed oligonucleotide probes, speciﬁcally designed to dis-
tinguish converted from unconverted CpG sites. The ABC
method allowed subsequent attachment of avidin–
biotinylated peroxidase conjugating onto the DNA chain
through speciﬁc binding between biotin and avidin (14,15).
Subsequently, the addition of 4,4,40,40-tetramethyl benzidine
generated an insoluble purple signal on the slide surface
(14,15).
Microarray-based methylation analysis
We examined the feasibility of our strategy by assessing the
methylation status of 12 CpG sites located in the exon 1 of
the MGMT gene (Figure 2A). A group of eight-arrayed
oligonucleotides (19 nt in length) was designed to test the
methylation status of 12 CpG sites within the promoter region.
Each set contained a pair of methylated and unmethylated
oligonucleotides for interrogating 2–4 CpG sites in close prox-
imity (Figure 2B). First, control DNA from fully-methylated
and non-methylated samples was used to test the accuracy and
reproducibility of our system.
To exclude experimental variability, the oligonucleotide
arrays used for these comparative assays were all derived
from the same quality-controlled spotting batch. To quantify
the target/probe hybridization sensitivity and linearity,
methylation arrays were manufactured with a ﬁxed
amount of an oligonucleotide. Then, the arrays were hybrid-
ized with mixtures of biotinylated DNA targets from fully-
methylated and non-methylated samples at different
proportions representing 0, 25, 50, 75 and 100% of DNA
methylation. Figure 3A shows a typical image of hybridization
signal intensities from these experiments. Irrespective of
methylation proportions, hybridization was speciﬁc to the
Figure 1. Methylation microarray procedure for the analysis of hybridization
data. Genomic DNA was treated with bisulfite and amplified for a specific
region of interest containing multiple CpG islands by PCR. PCR product was
labeled with biotin and hybridized to the oligonucleotide arrays. Hybridization
signals on the array were visualized by the ABC method.
PAGE 3 OF 8 Nucleic Acids Research, 2005, Vol. 33, No. 5 e46complementary probe DNA. The average intensity of
hybridization signals for the methylated (M) and unmethy-
lated (U) alleles was derived from the duplicate spots. The
intensity ratio was calculated by M/(M + U). In all the cases,
a linear relationship (R
2 = 0.948–0.988) was observed
(Figure 3B). This indicates that DNA methylation and the
intensity ratios in the control samples increased proportion-
ally, allowing the determination of the methylation status for
the test materials in question.
To further investigate whether our system can be applicable
to the mosaic methylation patterns, we prepared a set of PCR
products derived from genomic DNA with mosaic methylation
patterns, and the PCR products were then hybridized to the
arrays. We used the standard curves derived from the afore-
mentioned calibration controls as shown in Figure 3B to deter-
mine the methylation level in individual sample DNA, and
compared the results with those obtained by bisulﬁte sequen-
cing (Figure 4A). The percentage of methylation levels with
bisulﬁte sequencing was calculated by dividing the total num-
ber of methylated sites at each probe locus by the total number
of corresponding CpG loci analyzed and then multiplying by
100. However, as shown in Figure 4B, our system sometimes
quantitatively underestimated the methylation levels of par-
tially methylated samples [i.e. the methylation level of probe 2
with target (ii) and the methylation levels of probes 2–4 with
target (iii)] compared with the sequencing results. Methylation
levels measured by the microarray, however, still showed a
relatively good correlation (R
2 = 0.776) with the data obtained
from bisulﬁte sequencing. This discordance may be owing to
the fact that the intensity and speciﬁcity of the hybridization
signal can intricately vary depending on the number and posi-
tion of the base pair mismatches at each probe, as described
previously (17). Accordingly, precise assessment of the
methylation status of partially methylated samples is technic-
ally a little more challenging.
Microarray analysis utilizing clinical samples
To apply and assessthe general performance of ourmicroarray
strategy to DNA methylation analysis, we then analyzed the
methylation status of DNA in CRC tissues and the correspond-
ing normal mucosal samples from 12 patients, in which the
methylation status of MGMT was already known (3). The
biotinylated target DNA was prepared from corresponding
bisulﬁte-treated genomic DNA (see Materials and Methods)
in order to avoid extremely labor-intensive and time-
consuming sample cloning.
Figure5showsthemethylationlevelsof12CRCtissuesand
12 corresponding normal mucosal tissues determined by the
microarray. With the use of the standard curves derived from
the aforementioned calibration controls (Figure 3B), extensive
methylation of the MGMT CpG sites was observed in CRC
tissues and little or no methylation was detected in normal
mucosal samples (Figure 5). These microarray results we
examined were generally consistent with a previously determ-
ined methylation status by MSP method (3,18).
To further validate our microarray ﬁndings in normal and
tumor samples, we compared these microarray outcome with
that of the bisulﬁte sequencing of the cloned PCR products
from the same samples. Figure 6 shows the methylation status
of 12 CpG pairs in the MGMT promoter of normal and tumor
tissue samples determined by bisulﬁte sequencing. Although
bisulﬁte sequencing showed extensive methylation in the
tumor samples comparative with the microarray results, sev-
eral samples showed underestimated results by the microarray
system compared with those by bisulﬁte sequencing. This was
cggatatgctgggacagcccgcgcccctagaacgctttgcgtcccgacgcccgcag
1         2  3     4    5
gtcctcgcggtgcgcaccgtttgcgacttggtgagtgtctgggtcgcctcgctcccgga
6  7       8        9       10     11       12
A
B
Probe No. MGMT CpG locus          Oligonucleotide sequence       Tm (ºC)
1           1, 2                        M  5' ACGCAAAACGTTCTAAAAA 3'         64.3
U  5' ACACAAAACATTCTAAAAA 3'          60.0
2          2, 3, 4, 5                M  5' CTACGAACGTCGAAACGCA 3'       72.9
U  5' CTACAAACATCAAAACACA 3'          64.3
3               6, 7, 8, 9  M  5' CAAACGATACGCACCGCGA 3'        75.1
U  5' CAAACAATACACACCACAA 3'          66.5
4               10, 11, 12              M  5' CTCTTC CGAAAACGAAACG 3'      70.8
U  5' CTCTTCCAAAAACAAAACA 3'         64.3
Figure 2. Promoter sequence of human MGMT. The 12 CpG sites located in exon 1 tested in this study were underlined and shown in bold (A). The sequence
including CpG sites and the Tm of the methylated and unmethylated oligonucleotide probes are shown (B).
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target alleles—they might have decreased the methylation
levels by disturbing hybridization as shown in Figure 4B.
Bisulﬁte sequencing with methylated-speciﬁc primers showed
a high level of methylation in sample 286N within the
sequence analyzed (Figure 6) and were discordant with
the microarray outcome (Figure 5). This may indicate that the
microarray analysis might fail to detect an MGMT methylation
in part of the normal epithelium in 286N sample. Conversely,
in the case of 291N, we could not ﬁnd any methylation within
the promoter region by the bisulﬁte sequencing (Figure 6),
whereas the microarray analysis identiﬁed weak methylation
in part of the MGMT promoter (Figure 5). A previous study,
however,indicated the absenceof methylationin sample 286N
and the presence of methylation in sample 291N by the
bisulﬁte-PCR-single-strand DNA conformation polymorph-
ism analysis (18). This discrepancy can be explained by the
different CpG islands targeted by each methodology.
DISCUSSION
In this study, we described a simple and rapid technique to
analyze DNA methylation status achieved by the combination
of bisulﬁte DNA treatment, oligonucleotide microarray and
ABC detection system. Our alternative microarray system
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the MGMT promoter of DNA derived from both cultured cells
and clinical samples (3).
One possible drawback of our system can be the narrow
dynamic range of our image scanning system that may limit
the quantitative determination. Although the ﬂuorescent sys-
tem commonly used in microarray analysis in combination
with the expensive readout laser scanner is able to read the
images with 65535 tones (19), the commercially available
scanner used in this study was originally developed forimport-
ing images from papers or pictures and read the images of only
255 tones. Nonetheless, this study showed that our microarray
systemcouldquantitativelydetectthemethylationstatusofthe
fully- or non-methylated DNA (Figure 3B). Sensitivity can be
increased by the use of biotin–dCTP instead of dCTP during
PCR in our microarray system because all samples are ﬁnally
prepared by PCR. Also, the biotin–avidin alkaline phosphatase
indicator system, which is very convenient and easy to use,
was employed to increase the sensitivity. This indicated that
our microarray system is reliable enough to discern promoter
hypermethylation event that occur in cancer-related genes.
In initial study of these microarray assays, cross-
hybridization between imperfect-match probes and targets
was sometimes observed (data not shown), which can be
observed in other oligonucleotide microarrays. In order to
design optimal sequence composition for each oligonucleotide
probe, we realized that at least two CpG sites should be
included in each probe in our assay. However, as shown in
Figure 4B, strict quantiﬁcation of methylated CpG sites was
sometimes hard if the target promoter has mosaic methylation
patterns. In addition, this method could not distinguish par-
tially methylated DNA and heterogeneous sample consisting
of fully- and non-methylated DNA. Nevertheless, for the pur-
pose of assessing gene silencing in the clinical samples,
A
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ant than speciﬁc methylation that occur at single CpG island
(20,21).
In the present study, we compared our methylation microar-
ray system with the bisulﬁte-sequencing method through the
analysis of MGMT promoter. Our array method successfully
demonstrated methylation status of individual samples com-
parable with those obtained by the conventional bisulﬁte
sequencing. However, we observed a few samples that
revealed different methylation status between the two meth-
odologies. Although the bisulﬁte sequencing provides com-
plete and reliable methylation proﬁles of each CpG site, it
requires extremely labor-intensive and time-consuming clon-
ing prior to sequencing procedures and this may limit its
ability to high-throughput sample analysis. Commonly used
MSP has also limited its utility by hybridization speciﬁcity of
primers and, thus, potentially gives false-positive and false-
negative results. Therefore, a simple, robust and inexpensive
alternative method, which allows quantitative high-throughput
assays to determine the exact location responsible for the
silencing of the gene promoter, especially for clinical samples,
is desired. Our methylation-array system may fulﬁll this
requirement. Although the precise experimental design is a
prerequisite, the results derived from a number of samples in
comparison with bisulﬁte sequencing strongly support the pro-
position that our precise microarray system can determine the
actual methylation levels.
In conclusion, the present technique can be readily recon-
ﬁgured for high-throughput analysis of DNA methylation.
Although our technique needs further improvement in its
application to the high-throughput system, we believe that
this technique may contribute to the comprehensive under-
standing of the cancer epigenetics, as well as the clinical
applications.
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the inserts were sequenced. The nucleotide positions of these CpG sites are
shown in Figure 2A and B. The fraction of clones with methylated cytosine in
each CpG sites (% methylation) is shown. Each value is derived from four
clones.
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